Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWRNASDAQ:MDCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$10.68-11.4%$17.31$10.49▼$30.41$1.47B0.921.36 million shs2.57 million shsMDCOMedicines$84.90$84.90$17.81▼$84.98$6.77B1.19.55 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-4.96%-12.61%-29.51%-39.06%-54.46%MDCOMedicines0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.0528 of 5 stars3.31.00.03.41.62.50.0MDCOMedicinesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.60Moderate Buy$41.44288.06% UpsideMDCOMedicines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MDCO and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/14/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $38.002/12/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.002/11/2025ARWRArrowhead PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.002/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.001/23/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$2.50M586.62N/AN/A$1.54 per share6.94MDCOMedicines$6.14M1,102.36N/AN/A($0.30) per share-283.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$5.17N/AN/AN/AN/A-236.60%-64.09%5/8/2025 (Estimated)MDCOMedicines-$123.16M-$2.91N/AN/AN/AN/AN/A-25.70%N/ALatest MDCO and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/10/2025Q1 2025ARWRArrowhead Pharmaceuticals-$0.42-$1.39-$0.97-$1.39$19.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AMDCOMedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals7.276.096.09MDCOMedicines21.450.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%MDCOMedicinesN/AInsider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%MDCOMedicines8.41%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400137.32 million120.68 millionOptionableMDCOMedicines6279.72 millionN/AOptionableMDCO and ARWR HeadlinesRecent News About These CompaniesPraxis Precision Medicines to Participate in Upcoming April ConferencesApril 3 at 6:18 PM | gurufocus.comSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines ...April 3 at 5:32 PM | gurufocus.comPraxis Precision Medicines to Participate in Upcoming April ConferencesApril 3 at 5:32 PM | gurufocus.comRevolution Medicines Inc (RVMD) to Present at AACR Annual Meeting 2025April 1 at 5:38 PM | gurufocus.comEverest Medicines Announces New Share Option and Award GrantsApril 1 at 10:57 AM | tipranks.comRevolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy NowMarch 31, 2025 | insidermonkey.com3D Medicines Inc. Reports 2024 Financial Results Amid Market ChallengesMarch 31, 2025 | tipranks.com3D Medicines Inc. Forms Nomination Committee for Enhanced GovernanceMarch 31, 2025 | tipranks.com3D Medicines Announces Board Composition and Governance StructureMarch 31, 2025 | tipranks.comIs Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy?March 30, 2025 | insidermonkey.comIs Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy?March 30, 2025 | insidermonkey.comBlueprint Medicines: Strong Business, Ambitious Targets, Expensive StockMarch 29, 2025 | seekingalpha.comEuropean committee says Lilly Alzheimer’s drug shouldn’t get marketing approvalMarch 28, 2025 | financialpost.comEuropean committee says Lilly Alzheimer's drug shouldn't get marketing approvalMarch 28, 2025 | marketbeat.comEuropean Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11March 28, 2025 | financialpost.comTYK Medicines Reports 2024 Annual Results and Corporate ChangesMarch 27, 2025 | tipranks.comFull Year 2024 Everest Medicines Ltd Earnings Call TranscriptMarch 27, 2025 | gurufocus.comEverest Medicines Ltd (FRA:6HN) (Full Year 2024) Earnings Call Highlights: Record Revenue ...March 27, 2025 | gurufocus.comUK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair ® (omalizumab)March 26, 2025 | investing.comEverest Medicines Announces Financial Results for Full Year Ended December 31, 2024March 25, 2025 | investing.comIs Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street AnalystsMarch 25, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCO and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$10.68 -1.38 (-11.44%) Closing price 04:00 PM EasternExtended Trading$10.94 +0.26 (+2.43%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Medicines NASDAQ:MDCOThe Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
